The Ministry of Food and Drug Safety (MFDS) said on Thursday that it has approved an orphan drug Elrexfio (elranatamab), imported by Pfizer Korea.
The drug is indicated as monotherapy in adult patients with relapsed or refractory multiple myeloma who have received three or more prior therapies, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.
Elrexfio destroys multiple myeloma cancer cells in an immune response by targeting B-cell maturation antigen (BCMA) found on multiple myeloma cancer cells and CD3 found on immune T cells, binding bispecifically to both cells.
The ministry said it expects the drug to provide new treatment opportunities for patients with relapsed or refractory multiple myeloma who have received three or more lines of treatment.
Related articles
- Sanofi's Sarclisa awaits FDA review for expanded 1st-line multiple myeloma treatment
- New research offers hope in multiple myeloma treatment through enhanced NK cell function
- Darzalex’s reimbursement has been in limbo for 3 years. Will it be different this time?
- New blood cancer drugs reach Korea but insurance delays hinder survival rates: expert
- Lenalidomide plays vital role in multiple myeloma, creates immunotherapy synergies: hematologist
- 5-year survival rate for Korean multiple myeloma patients nearly doubles, yet access to new treatments still limited: IQVIA